Cowen, Needham, Canaccord Genuity are the bookrunners; BTIG to assist
By Devika Patel
Knoxville, Tenn., Dec. 2 – Histogenics Corp. said it priced its $65 million initial public offering of stock with a $9.75 million greenshoe. The deal was announced Oct. 7.
The company will sell 5,909,091 common shares at $11.00 apiece.
Cowen and Co., LLC, Needham & Co., LLC and Canaccord Genuity Inc. are the bookrunning managers.
Sofinnova Venture Partners, Split Rock Partners and Wilmslow Estates Ltd. may invest up to $15 million. Intrexon Corp. plans to invest $15 million.
Proceeds will be used to develop and advance NeoCart and to build out manufacturing facilities, as well as for working capital and general corporate purposes.
The regenerative medicine company is based in Waltham, Mass. It intends to list its common stock on the Nasdaq under the symbol “HSGX.”
| Issuer: | Histogenics Corp.
|
| Issue: | Common stock
|
| Amount: | $65 million
|
| Greenshoe: | $9.75 million
|
| Shares: | 5,909,091
|
| Price: | $11.00
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co., LLC, Needham & Co., LLC and Canaccord Genuity Inc.
|
| Co-manager: | BTIG, LLC
|
| Announcement date: | Oct. 7
|
| Pricing date: | Dec. 2
|
| Stock exchange: | Nasdaq: HSGX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
